-
F.
Grossi,
L.
Crinò,
A.
Logroscino,
S.
Canova,
A.
Delmonte,
B.
Melotti,
C.
Proto,
A.
Gelibter,
F.
Cappuzzo,
D.
Turci,
T.
Gamucci,
P.
Antonelli,
P.
Marchetti,
A.
Santoro,
S.
Giusti,
F.
Costanzo,
L.
Giustini,
A.
Conte,
L.
Livi,
D.
Giannarelli,
F.
Marinis
(2018)
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.
European journal of cancer, 100
-
(
BorghaeiHPaz-AresLHornL, et al
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med
2015; 373: 1627–1639.26412456)
BorghaeiHPaz-AresLHornL, et al
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med
2015; 373: 1627–1639.26412456
BorghaeiHPaz-AresLHornL, et al
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med
2015; 373: 1627–1639.26412456,
BorghaeiHPaz-AresLHornL, et al
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med
2015; 373: 1627–1639.26412456
-
A.
Berghoff,
V.
Venur,
M.
Preusser,
M.
Ahluwalia
(2016)
Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment.
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 35
-
G.
Galli,
A.
Toma,
F.
Pagani,
G.
Randon,
B.
Trevisan,
A.
Prelaj,
R.
Ferrara,
C.
Proto,
D.
Signorelli,
M.
Ganzinelli,
N.
Zilembo,
F.
Braud,
M.
Garassino,
G.
Russo
(2019)
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer.
Lung cancer, 137
-
(
GavrilovicITPosnerJB
Brain metastases: epidemiology and pathophysiology. J Neurooncol
2005; 75: 5–14.16215811)
GavrilovicITPosnerJB
Brain metastases: epidemiology and pathophysiology. J Neurooncol
2005; 75: 5–14.16215811
GavrilovicITPosnerJB
Brain metastases: epidemiology and pathophysiology. J Neurooncol
2005; 75: 5–14.16215811,
GavrilovicITPosnerJB
Brain metastases: epidemiology and pathophysiology. J Neurooncol
2005; 75: 5–14.16215811
-
(2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
-
(
GrayN
The consequences of the unregulated cigarette. Tob Control
2006; 15: 405–408.16998176)
GrayN
The consequences of the unregulated cigarette. Tob Control
2006; 15: 405–408.16998176
GrayN
The consequences of the unregulated cigarette. Tob Control
2006; 15: 405–408.16998176,
GrayN
The consequences of the unregulated cigarette. Tob Control
2006; 15: 405–408.16998176
-
Suneel
Kamath,
P.
Kumthekar
(2018)
Immune Checkpoint Inhibitors for the Treatment of Central Nervous System (CNS) Metastatic Disease
Frontiers in Oncology, 8
-
(
OwenSSouhamiL
The management of brain metastases in non-small cell lung cancer. Front Oncol
2014; 4: 248.25309873)
OwenSSouhamiL
The management of brain metastases in non-small cell lung cancer. Front Oncol
2014; 4: 248.25309873
OwenSSouhamiL
The management of brain metastases in non-small cell lung cancer. Front Oncol
2014; 4: 248.25309873,
OwenSSouhamiL
The management of brain metastases in non-small cell lung cancer. Front Oncol
2014; 4: 248.25309873
-
G.
Pawelec
(2012)
Hallmarks of human “immunosenescence”: adaptation or dysregulation?
Immunity & Ageing : I & A, 9
-
R.
Ferrara,
L.
Mezquita,
E.
Auclin,
N.
Chaput,
B.
Besse
(2017)
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?
Cancer treatment reviews, 60
-
R.
Ferrara,
M.
Naigeon,
E.
Auclin,
B.
Duchemann,
L.
Cassard,
J.
Medhi,
L.
Boselli,
J.
Grivel,
A.
Desnoyer,
L.
Mezquita,
L.
Hendriks,
D.
Planchard,
C.
Caramella,
J.
Remon-Masip,
S.
Sangaletti,
M.
Garassino,
B.
Besse,
N.
Chaput
(2019)
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts).
Annals of oncology : official journal of the European Society for Medical Oncology, 30 Suppl 2
-
Stijn
Keukeleire,
T.
Vermassen,
G.
Schoenmakere,
V.
Kruse,
K.
Vermaelen,
S.
Rottey
(2020)
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition
Acta Clinica Belgica, 75
-
(
TawbiHAForsythPAAlgaziA, et al
Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med
2018; 379: 722–730.30134131)
TawbiHAForsythPAAlgaziA, et al
Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med
2018; 379: 722–730.30134131
TawbiHAForsythPAAlgaziA, et al
Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med
2018; 379: 722–730.30134131,
TawbiHAForsythPAAlgaziA, et al
Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med
2018; 379: 722–730.30134131
-
(
PostowMACallahanMKWolchokJD
Immune checkpoint blockade in cancer therapy. J Clin Oncol
2015; 33: 1974–1982.25605845)
PostowMACallahanMKWolchokJD
Immune checkpoint blockade in cancer therapy. J Clin Oncol
2015; 33: 1974–1982.25605845
PostowMACallahanMKWolchokJD
Immune checkpoint blockade in cancer therapy. J Clin Oncol
2015; 33: 1974–1982.25605845,
PostowMACallahanMKWolchokJD
Immune checkpoint blockade in cancer therapy. J Clin Oncol
2015; 33: 1974–1982.25605845
-
(
ManoharSLeungN
Cisplatin nephrotoxicity: a review of the literature. J Nephrol
2018; 31: 15–25.28382507)
ManoharSLeungN
Cisplatin nephrotoxicity: a review of the literature. J Nephrol
2018; 31: 15–25.28382507
ManoharSLeungN
Cisplatin nephrotoxicity: a review of the literature. J Nephrol
2018; 31: 15–25.28382507,
ManoharSLeungN
Cisplatin nephrotoxicity: a review of the literature. J Nephrol
2018; 31: 15–25.28382507
-
(
LocherCDebieuvreDCoetmeurD, et al
Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. Lung Cancer
2013; 81: 32–38.23541463)
LocherCDebieuvreDCoetmeurD, et al
Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. Lung Cancer
2013; 81: 32–38.23541463
LocherCDebieuvreDCoetmeurD, et al
Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. Lung Cancer
2013; 81: 32–38.23541463,
LocherCDebieuvreDCoetmeurD, et al
Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies. Lung Cancer
2013; 81: 32–38.23541463
-
(
IzzedineH
[Pemetrexed nephrotoxicity]. Bull Cancer
2015; 102: 190–197.25641712)
IzzedineH
[Pemetrexed nephrotoxicity]. Bull Cancer
2015; 102: 190–197.25641712
IzzedineH
[Pemetrexed nephrotoxicity]. Bull Cancer
2015; 102: 190–197.25641712,
IzzedineH
[Pemetrexed nephrotoxicity]. Bull Cancer
2015; 102: 190–197.25641712
-
(
BerghoffASVenurVAPreusserM, et al
Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book
2016; 35: e116–e122.27249713)
BerghoffASVenurVAPreusserM, et al
Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book
2016; 35: e116–e122.27249713
BerghoffASVenurVAPreusserM, et al
Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book
2016; 35: e116–e122.27249713,
BerghoffASVenurVAPreusserM, et al
Immune checkpoint inhibitors in brain metastases: from biology to treatment. Am Soc Clin Oncol Educ Book
2016; 35: e116–e122.27249713
-
Shiqiang
Wang,
Chongling
Hu,
Fei
Xie,
Yanhui
Liu
(2020)
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
OncoTargets and therapy, 13
-
(
GrossiFCrinoLLogroscinoA, et al
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer
2018; 100: 126–134.30014881)
GrossiFCrinoLLogroscinoA, et al
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer
2018; 100: 126–134.30014881
GrossiFCrinoLLogroscinoA, et al
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer
2018; 100: 126–134.30014881,
GrossiFCrinoLLogroscinoA, et al
Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme. Eur J Cancer
2018; 100: 126–134.30014881
-
(
CorreRGreillierLLe CaerH, et al
Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol
2016; 34: 1476–1483.26884557)
CorreRGreillierLLe CaerH, et al
Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol
2016; 34: 1476–1483.26884557
CorreRGreillierLLe CaerH, et al
Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol
2016; 34: 1476–1483.26884557,
CorreRGreillierLLe CaerH, et al
Use of a comprehensive geriatric assessment for the management of elderly patients with advanced non-small-cell lung cancer: the phase III randomized ESOGIA-GFPC-GECP 08-02 study. J Clin Oncol
2016; 34: 1476–1483.26884557
-
J.
Brahmer,
K.
Reckamp,
P.
Baas,
L.
Crinò,
W.
Eberhardt,
E.
Poddubskaya,
S.
Antonia,
A.
Płużański,
E.
Vokes,
E.
Holgado,
D.
Waterhouse,
N.
Ready,
J.
Gainor,
O.
Frontera,
L.
Havel,
M.
Steins,
M.
Garassino,
J.
Aerts,
M.
Dómine,
L.
Paz-Ares,
M.
Reck,
C.
Baudelet,
C.
Harbison,
B.
Lestini,
D.
Spigel
(2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 2
-
F.
Barlesi,
A.
Dixmier,
D.
Debieuvre,
C.
Raspaud,
J.
Auliac,
N.
Benoit,
P.
Bombaron,
D.
Moro-Sibilot,
C.
Audigier-Valette,
B.
Asselain,
T.
Egenod,
A.
Rabeau,
J.
Fayette,
M.
Sanchez,
J.
Labourey,
V.
Westeel,
P.
Lamoureux,
F.
Cotté,
V.
Allan,
M.
Daumont,
J.
Dumanoir,
D.
Reynaud,
C.
Calvet,
N.
Ozan,
M.
Pérol
(2020)
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study
Oncoimmunology, 9
-
S.
Parakh,
John
Park,
S.
Mendis,
R.
Rai,
Wen
Xu,
S.
Lo,
M.
Drummond,
C.
Rowe,
Annie
Wong,
G.
McArthur,
A.
Haydon,
M.
Andrews,
J.
Cebon,
A.
Guminski,
R.
Kefford,
G.
Long,
A.
Menzies,
O.
Klein,
M.
Carlino
(2016)
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases
British Journal of Cancer, 116
-
(
ShiraliACPerazellaMAGettingerS
Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis
2016; 68: 287–291.27113507)
ShiraliACPerazellaMAGettingerS
Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis
2016; 68: 287–291.27113507
ShiraliACPerazellaMAGettingerS
Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis
2016; 68: 287–291.27113507,
ShiraliACPerazellaMAGettingerS
Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis
2016; 68: 287–291.27113507
-
Leena
Gandhi,
M.
Garassino
(2018)
Pembrolizumab plus Chemotherapy in Lung Cancer.
The New England journal of medicine, 379 11
-
Saskia
Herz,
T.
Höfer,
M.
Papapanagiotou,
Julia
Leyh,
Sarah
Meyenburg,
D.
Schadendorf,
S.
Ugurel,
A.
Roesch,
E.
Livingstone,
B.
Schilling,
C.
Franklin
(2016)
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.
European journal of cancer, 67
-
Cyrus
Chargari,
F.
Dhermain
(2013)
Métastases cérébrales d’un cancer bronchique non à petites cellules : du traitement standardisé au traitement personnalisé
Revue des Maladies Respiratoires Actualités, 5
-
E.
Nadal,
B.
Massutí,
M.
Dómine,
R.
García-Campelo,
M.
Cobo,
E.
Felip
(2019)
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
Cancer Immunology, Immunotherapy, 68
-
H.
Caer,
I.
Borget,
R.
Corre,
C.
Locher,
C.
Raynaud,
C.
Decroisette,
H.
Bérard,
C.
Audigier-Valette,
C.
Dujon,
J.
Auliac,
J.
Crequit,
I.
Monnet,
A.
Vergnenègre,
C.
Chouaid
(2017)
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.
Journal of thoracic disease, 9 10
-
(
PlanchardDPopatSKerrK, et al
Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2018; 29: iv192–iv237.)
PlanchardDPopatSKerrK, et al
Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2018; 29: iv192–iv237.
PlanchardDPopatSKerrK, et al
Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2018; 29: iv192–iv237.,
PlanchardDPopatSKerrK, et al
Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol
2018; 29: iv192–iv237.
-
I.
Gavrilovic,
J.
Posner
(2005)
Brain metastases: epidemiology and pathophysiology
Journal of Neuro-Oncology, 75
-
(
GisquetEAoubaAAubryR, et al
Où meurt-on en France? Analyse des certificats de décès (1993-2008). Bull Epidemiol Hebd
2012; 48: 547–551.)
GisquetEAoubaAAubryR, et al
Où meurt-on en France? Analyse des certificats de décès (1993-2008). Bull Epidemiol Hebd
2012; 48: 547–551.
GisquetEAoubaAAubryR, et al
Où meurt-on en France? Analyse des certificats de décès (1993-2008). Bull Epidemiol Hebd
2012; 48: 547–551.,
GisquetEAoubaAAubryR, et al
Où meurt-on en France? Analyse des certificats de décès (1993-2008). Bull Epidemiol Hebd
2012; 48: 547–551.
-
E.
Felip,
A.
Ardizzoni,
T.
Ciuleanu,
M.
Cobo,
K.
Laktionov,
M.
Szilasi,
R.
Califano,
E.
Carcereny,
R.
Griffiths,
L.
Paz-Ares,
R.
Duchnowska,
Miriam
García,
D.
Isla,
J.
Jassem,
W.
Appel,
J.
Milanowski,
J.
Meerbeeck,
J.
Wolf,
A.
Li,
A.
Acevedo,
S.
Popat
(2020)
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations.
European journal of cancer, 127
-
(
BironzoPDi MaioM
A review of guidelines for lung cancer. J Thorac Dis
2018; 10: S1556–S1563.29951306)
BironzoPDi MaioM
A review of guidelines for lung cancer. J Thorac Dis
2018; 10: S1556–S1563.29951306
BironzoPDi MaioM
A review of guidelines for lung cancer. J Thorac Dis
2018; 10: S1556–S1563.29951306,
BironzoPDi MaioM
A review of guidelines for lung cancer. J Thorac Dis
2018; 10: S1556–S1563.29951306
-
(
GauvainCVauleonEChouaidC, et al
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer
2018; 116: 62–66.29413052)
GauvainCVauleonEChouaidC, et al
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer
2018; 116: 62–66.29413052
GauvainCVauleonEChouaidC, et al
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer
2018; 116: 62–66.29413052,
GauvainCVauleonEChouaidC, et al
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases. Lung Cancer
2018; 116: 62–66.29413052
-
P.
Bironzo,
M.
Maio
(2018)
A review of guidelines for lung cancer.
Journal of thoracic disease, 10 Suppl 13
-
(
DumenilCMassianiMADumoulinJ, et al
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS One
2018; 13: e0195945.29684049)
DumenilCMassianiMADumoulinJ, et al
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS One
2018; 13: e0195945.29684049
DumenilCMassianiMADumoulinJ, et al
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS One
2018; 13: e0195945.29684049,
DumenilCMassianiMADumoulinJ, et al
Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. PLoS One
2018; 13: e0195945.29684049
-
(
FerraraRMezquitaLAuclinE, et al
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?
Cancer Treat Rev
2017; 60: 60–68.28889085)
FerraraRMezquitaLAuclinE, et al
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?
Cancer Treat Rev
2017; 60: 60–68.28889085
FerraraRMezquitaLAuclinE, et al
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?
Cancer Treat Rev
2017; 60: 60–68.28889085,
FerraraRMezquitaLAuclinE, et al
Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: does age really matter?
Cancer Treat Rev
2017; 60: 60–68.28889085
-
(
SabatinoARegolistiGKarupaiahT, et al
Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nutr
2017; 36: 663–671.27371993)
SabatinoARegolistiGKarupaiahT, et al
Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nutr
2017; 36: 663–671.27371993
SabatinoARegolistiGKarupaiahT, et al
Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nutr
2017; 36: 663–671.27371993,
SabatinoARegolistiGKarupaiahT, et al
Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis. Clin Nutr
2017; 36: 663–671.27371993
-
(
BrahmerJReckampKLBaasP, et al
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med
2015; 373: 123–135.26028407)
BrahmerJReckampKLBaasP, et al
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med
2015; 373: 123–135.26028407
BrahmerJReckampKLBaasP, et al
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med
2015; 373: 123–135.26028407,
BrahmerJReckampKLBaasP, et al
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med
2015; 373: 123–135.26028407
-
H.
Izzedine
(2015)
[Pemetrexed nephrotoxicity].
Bulletin du cancer, 102 2
-
B.
Youn,
N.
Trikalinos,
V.
Mor,
I.
Wilson,
I.
Dahabreh
(2020)
Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer
Cancer, 126
-
(
KamathSDKumthekarPU
Immune checkpoint inhibitors for the treatment of Central Nervous System (CNS) metastatic disease. Front Oncol
2018; 8: 414.30319977)
KamathSDKumthekarPU
Immune checkpoint inhibitors for the treatment of Central Nervous System (CNS) metastatic disease. Front Oncol
2018; 8: 414.30319977
KamathSDKumthekarPU
Immune checkpoint inhibitors for the treatment of Central Nervous System (CNS) metastatic disease. Front Oncol
2018; 8: 414.30319977,
KamathSDKumthekarPU
Immune checkpoint inhibitors for the treatment of Central Nervous System (CNS) metastatic disease. Front Oncol
2018; 8: 414.30319977
-
K.
Hargadon,
Coleman
Johnson,
C.
Williams
(2018)
Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
International immunopharmacology, 62
-
C.
Chouaïd,
D.
Debieuvre,
I.
Durand-zaleski,
J.
Fernandes,
A.
Scherpereel,
V.
Westeel,
C.
Blein,
A.
Gaudin,
N.
Ozan,
Soline
Leblanc,
A.
Vainchtock,
P.
Chauvin,
F.
Cotté,
P.
Souquet
(2017)
Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
PLoS ONE, 12
-
J.
Lortet-Tieulent,
I.
Soerjomataram,
J.
Ferlay,
M.
Rutherford,
E.
Weiderpass,
F.
Bray
(2014)
International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women.
Lung cancer, 84 1
-
P.
Tuppin,
J.
Rudant,
P.
Constantinou,
C.
Gastaldi-Ménager,
A.
Rachas,
L.
Roquefeuil,
G.
Maura,
H.
Caillol,
A.
Tajahmady,
J.
Coste,
C.
Gissot,
A.
Weill,
A.
Fagot-Campagna
(2017)
Value of a national administrative database to guide public decisions: From the système national d'information interrégimes de l'Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France.
Revue d'epidemiologie et de sante publique, 65 Suppl 4
-
Stacey
Kenfield,
E.
Wei,
M.
Stampfer,
Bernard
Rosner,
G.
Colditz
(2008)
Comparison of aspects of smoking among the four histological types of lung cancer
Tobacco Control, 17
-
(
NadalEMassutiBDomineM, et al
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother
2019; 68: 341–352.30725206)
NadalEMassutiBDomineM, et al
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother
2019; 68: 341–352.30725206
NadalEMassutiBDomineM, et al
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother
2019; 68: 341–352.30725206,
NadalEMassutiBDomineM, et al
Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother
2019; 68: 341–352.30725206
-
(
De KeukeleireSVermassenTDe SchoenmakereG, et al
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. Acta Clin Belg. Epub ahead of print 29
7
2019 DOI: 10.1080/17843286.2019.1646516.)
De KeukeleireSVermassenTDe SchoenmakereG, et al
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. Acta Clin Belg. Epub ahead of print 29
7
2019 DOI: 10.1080/17843286.2019.1646516.
De KeukeleireSVermassenTDe SchoenmakereG, et al
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. Acta Clin Belg. Epub ahead of print 29
7
2019 DOI: 10.1080/17843286.2019.1646516.,
De KeukeleireSVermassenTDe SchoenmakereG, et al
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibition. Acta Clin Belg. Epub ahead of print 29
7
2019 DOI: 10.1080/17843286.2019.1646516.
-
H.
Borghaei,
L.
Paz-Ares,
L.
Horn,
D.
Spigel,
M.
Steins,
N.
Ready,
L.
Chow,
E.
Vokes,
E.
Felip,
E.
Holgado,
F.
Barlesi,
M.
Kohlhäufl,
O.
Arrieta,
M.
Burgio,
J.
Fayette,
H.
Léna,
E.
Poddubskaya,
D.
Gerber,
S.
Gettinger,
C.
Rudin,
N.
Rizvi,
L.
Crinò,
G.
Blumenschein,
S.
Antonia,
C.
Dorange,
C.
Harbison,
F.
Finckenstein,
J.
Brahmer
(2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 17
-
(
KenfieldSAWeiEKStampferMJ, et al
Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control
2008; 17: 198–204.18390646)
KenfieldSAWeiEKStampferMJ, et al
Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control
2008; 17: 198–204.18390646
KenfieldSAWeiEKStampferMJ, et al
Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control
2008; 17: 198–204.18390646,
KenfieldSAWeiEKStampferMJ, et al
Comparison of aspects of smoking among the four histological types of lung cancer. Tob Control
2008; 17: 198–204.18390646
-
(
HargadonKMJohnsonCEWilliamsCJ
Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39.29990692)
HargadonKMJohnsonCEWilliamsCJ
Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39.29990692
HargadonKMJohnsonCEWilliamsCJ
Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39.29990692,
HargadonKMJohnsonCEWilliamsCJ
Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol
2018; 62: 29–39.29990692
-
(
KanzBAPollackMHJohnpulleR, et al
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer
2016; 4: 60.27777770)
KanzBAPollackMHJohnpulleR, et al
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer
2016; 4: 60.27777770
KanzBAPollackMHJohnpulleR, et al
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer
2016; 4: 60.27777770,
KanzBAPollackMHJohnpulleR, et al
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction. J Immunother Cancer
2016; 4: 60.27777770
-
C.
Dumenil,
M.
Massiani,
J.
Dumoulin,
V.
Giraud,
S.
Labrune,
T.
Chinet,
E.
Leprieur
(2018)
Clinical factors associated with early progression and grade 3–4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab
PLoS ONE, 13
-
S.
Antonia,
H.
Borghaei,
S.
Ramalingam,
L.
Horn,
J.
Carpeño,
A.
Płużański,
M.
Burgio,
M.
Garassino,
L.
Chow,
S.
Gettinger,
L.
Crinò,
D.
Planchard,
C.
Butts,
A.
Drilon,
J.
Wójcik-Tomaszewska,
G.
Otterson,
S.
Agrawal,
A.
Li,
J.
Penrod,
J.
Brahmer
(2019)
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.
The Lancet. Oncology
-
(
Kutluk CenikBSunHGerberDE
Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer
2013; 80: 326–332.23499397)
Kutluk CenikBSunHGerberDE
Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer
2013; 80: 326–332.23499397
Kutluk CenikBSunHGerberDE
Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer
2013; 80: 326–332.23499397,
Kutluk CenikBSunHGerberDE
Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer. Lung Cancer
2013; 80: 326–332.23499397
-
(
DudnikEYust-KatzSNechushtanH, et al
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer
2016; 98: 114–117.27393516)
DudnikEYust-KatzSNechushtanH, et al
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer
2016; 98: 114–117.27393516
DudnikEYust-KatzSNechushtanH, et al
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer
2016; 98: 114–117.27393516,
DudnikEYust-KatzSNechushtanH, et al
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases. Lung Cancer
2016; 98: 114–117.27393516
-
(
Lortet-TieulentJSoerjomataramIFerlayJ, et al
International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer
2014; 84: 13–22.24524818)
Lortet-TieulentJSoerjomataramIFerlayJ, et al
International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer
2014; 84: 13–22.24524818
Lortet-TieulentJSoerjomataramIFerlayJ, et al
International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer
2014; 84: 13–22.24524818,
Lortet-TieulentJSoerjomataramIFerlayJ, et al
International trends in lung cancer incidence by histological subtype: adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer
2014; 84: 13–22.24524818
-
(
FerraraRNaigeonMAuclinE, et al
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts). Ann Oncol
2019; 30(Suppl. 2): ii7–ii8.)
FerraraRNaigeonMAuclinE, et al
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts). Ann Oncol
2019; 30(Suppl. 2): ii7–ii8.
FerraraRNaigeonMAuclinE, et al
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts). Ann Oncol
2019; 30(Suppl. 2): ii7–ii8.,
FerraraRNaigeonMAuclinE, et al
Immunosenescence (iSenescence) correlates with progression (PD) to PD-(L)1 inhibitors (IO) and not to platinum-chemotherapy (PCT) in advanced non-small cell lung cancer (aNSCLC) patients (pts). Ann Oncol
2019; 30(Suppl. 2): ii7–ii8.
-
E.
Dudnik,
S.
Yust-Katz,
H.
Nechushtan,
D.
Goldstein,
A.
Zer,
D.
Flex,
T.
Siegal,
N.
Peled
(2016)
Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases.
Lung cancer, 98
-
(
GalliGDe TomaAPaganiF, et al
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer
2019; 137: 38–42.31526910)
GalliGDe TomaAPaganiF, et al
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer
2019; 137: 38–42.31526910
GalliGDe TomaAPaganiF, et al
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer
2019; 137: 38–42.31526910,
GalliGDe TomaAPaganiF, et al
Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. Lung Cancer
2019; 137: 38–42.31526910
-
(
TamiyaMTamiyaAInoueT, et al
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One
2018; 13: e0192227.29470536)
TamiyaMTamiyaAInoueT, et al
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One
2018; 13: e0192227.29470536
TamiyaMTamiyaAInoueT, et al
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One
2018; 13: e0192227.29470536,
TamiyaMTamiyaAInoueT, et al
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: a retrospective multicenter trial. PLoS One
2018; 13: e0192227.29470536
-
(
Giaj LevraMCottéF-ECorreR, et al
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer
2020; 140: 99–106.31911324)
Giaj LevraMCottéF-ECorreR, et al
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer
2020; 140: 99–106.31911324
Giaj LevraMCottéF-ECorreR, et al
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer
2020; 140: 99–106.31911324,
Giaj LevraMCottéF-ECorreR, et al
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: a national data base analysis. Lung Cancer
2020; 140: 99–106.31911324
-
C.
Gauvain,
E.
Vauléon,
C.
Chouaid,
É.
Rhun,
L.
Jabot,
A.
Scherpereel,
F.
Viñas,
A.
Cortot,
I.
Monnet
(2018)
Intracerebral efficacy and tolerance of nivolumab in non-small-cell lung cancer patients with brain metastases.
Lung cancer, 116
-
Bridgette
Kanz,
Megan
Pollack,
Romany
Johnpulle,
I.
Puzanov,
L.
Horn,
A.
Morgans,
J.
Sosman,
Suthee
Rapisuwon,
R.
Conry,
Z.
Eroglu,
Douglas
Johnson
(2016)
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Journal for Immunotherapy of Cancer, 4
-
(
WeiYFChenJYLeeHS, et al
Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ Open
2018; 8: e019661.)
WeiYFChenJYLeeHS, et al
Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ Open
2018; 8: e019661.
WeiYFChenJYLeeHS, et al
Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ Open
2018; 8: e019661.,
WeiYFChenJYLeeHS, et al
Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study. BMJ Open
2018; 8: e019661.
-
(
Le CaerHBorgetICorreR, et al
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. J Thorac Dis
2017; 9: 3747–3754.29268382)
Le CaerHBorgetICorreR, et al
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. J Thorac Dis
2017; 9: 3747–3754.29268382
Le CaerHBorgetICorreR, et al
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. J Thorac Dis
2017; 9: 3747–3754.29268382,
Le CaerHBorgetICorreR, et al
Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. J Thorac Dis
2017; 9: 3747–3754.29268382
-
R.
Corre,
L.
Greillier,
Hervé
Caër,
C.
Audigier-Valette,
N.
Baize,
H.
Bérard,
L.
Falchero,
I.
Monnet,
É.
Dansin,
A.
Vergnenègre,
M.
Marcq,
C.
Decroisette,
J.
Auliac,
S.
Bota,
R.
Lamy,
B.
Massutí,
C.
Dujon,
M.
Pérol,
J.
Daurès,
R.
Descourt,
H.
Léna,
C.
Plassot,
C.
Chouaïd
(2016)
Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 34 13
-
N.
Gray
(2006)
The consequences of the unregulated cigarette
Tobacco Control, 15
-
S.
Manohar,
N.
Leung
(2018)
Cisplatin nephrotoxicity: a review of the literature
Journal of Nephrology, 31
-
(
HerzSHoferTPapapanagiotouM, et al
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer
2016; 67: 66–72.27614165)
HerzSHoferTPapapanagiotouM, et al
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer
2016; 67: 66–72.27614165
HerzSHoferTPapapanagiotouM, et al
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer
2016; 67: 66–72.27614165,
HerzSHoferTPapapanagiotouM, et al
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. Eur J Cancer
2016; 67: 66–72.27614165
-
S.
Owen,
L.
Souhami
(2014)
The Management of Brain Metastases in Non-Small Cell Lung Cancer
Frontiers in Oncology, 4
-
Bercin
Cenik,
Han
Sun,
D.
Gerber
(2013)
Impact of renal function on treatment options and outcomes in advanced non-small cell lung cancer.
Lung cancer, 80 3
-
(
TuppinPRudantJConstantinouP, et al
Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique
2017; 65(Suppl. 4): S149–S167.28756037)
TuppinPRudantJConstantinouP, et al
Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique
2017; 65(Suppl. 4): S149–S167.28756037
TuppinPRudantJConstantinouP, et al
Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique
2017; 65(Suppl. 4): S149–S167.28756037,
TuppinPRudantJConstantinouP, et al
Value of a national administrative database to guide public decisions: from the systeme national d’information interregimes de l’Assurance Maladie (SNIIRAM) to the systeme national des donnees de sante (SNDS) in France. Rev Epidemiol Sante Publique
2017; 65(Suppl. 4): S149–S167.28756037
-
(
YounBTrikalinosNAMorV, et al
Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer
2020; 126: 978–985.31943163)
YounBTrikalinosNAMorV, et al
Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer
2020; 126: 978–985.31943163
YounBTrikalinosNAMorV, et al
Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer
2020; 126: 978–985.31943163,
YounBTrikalinosNAMorV, et al
Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer
2020; 126: 978–985.31943163
-
(
CalifanoRGomesFAckermannCJ, et al
Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations?
Eur J Cancer
2020; 125: 1–11.31830688)
CalifanoRGomesFAckermannCJ, et al
Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations?
Eur J Cancer
2020; 125: 1–11.31830688
CalifanoRGomesFAckermannCJ, et al
Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations?
Eur J Cancer
2020; 125: 1–11.31830688,
CalifanoRGomesFAckermannCJ, et al
Immune checkpoint blockade for non-small cell lung cancer: what is the role in the special populations?
Eur J Cancer
2020; 125: 1–11.31830688
-
(
GioulbasanisIBaracosVEGiannousiZ, et al
Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol
2011; 22: 835–841.20937647)
GioulbasanisIBaracosVEGiannousiZ, et al
Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol
2011; 22: 835–841.20937647
GioulbasanisIBaracosVEGiannousiZ, et al
Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol
2011; 22: 835–841.20937647,
GioulbasanisIBaracosVEGiannousiZ, et al
Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history. Ann Oncol
2011; 22: 835–841.20937647
-
(
ChargariCDhermainF
Métastases cérébrales d’un cancer bronchique non à petites cellules: du traitement standardisé au traitement personnalisé. Revue des Maladies Respiratoires Actualités
2013; 5: 547–556.)
ChargariCDhermainF
Métastases cérébrales d’un cancer bronchique non à petites cellules: du traitement standardisé au traitement personnalisé. Revue des Maladies Respiratoires Actualités
2013; 5: 547–556.
ChargariCDhermainF
Métastases cérébrales d’un cancer bronchique non à petites cellules: du traitement standardisé au traitement personnalisé. Revue des Maladies Respiratoires Actualités
2013; 5: 547–556.,
ChargariCDhermainF
Métastases cérébrales d’un cancer bronchique non à petites cellules: du traitement standardisé au traitement personnalisé. Revue des Maladies Respiratoires Actualités
2013; 5: 547–556.
-
J.
Xia,
Lin
Wang,
Zhiheng
Ma,
Liping
Zhong,
Ying
Wang,
Yachan
Gao,
Liqun
He,
Xiao
Su
(2017)
Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta‐analysis of prospective cohort studies
Nephrology Dialysis Transplantation, 32
-
(
AntoniaSJBorghaeiHRamalingamSS, et al
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol
2019; 20: 1395–1408.31422028)
AntoniaSJBorghaeiHRamalingamSS, et al
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol
2019; 20: 1395–1408.31422028
AntoniaSJBorghaeiHRamalingamSS, et al
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol
2019; 20: 1395–1408.31422028,
AntoniaSJBorghaeiHRamalingamSS, et al
Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. Lancet Oncol
2019; 20: 1395–1408.31422028
-
(
ParakhSParkJJMendisS, et al
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer
2017; 116: 1558–1563.28524161)
ParakhSParkJJMendisS, et al
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer
2017; 116: 1558–1563.28524161
ParakhSParkJJMendisS, et al
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer
2017; 116: 1558–1563.28524161,
ParakhSParkJJMendisS, et al
Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer
2017; 116: 1558–1563.28524161
-
M.
Levra,
F.
Cotté,
R.
Corre,
C.
Calvet,
A.
Gaudin,
J.
Penrod,
V.
Grumberg,
B.
Jouaneton,
R.
Jolivel,
J.
Assié,
C.
Chouaïd
(2019)
Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis.
Lung cancer, 140
-
R.
Califano,
F.
Gomes,
C.
Ackermann,
S.
Rafee,
G.
Tsakonas,
S.
Ekman
(2019)
Immune checkpoint blockade for non-small cell lung cancer: What is the role in the special populations?
European journal of cancer, 125
-
(
XiaJWangLMaZ, et al
Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant
2017; 32: 475–487.28339863)
XiaJWangLMaZ, et al
Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant
2017; 32: 475–487.28339863
XiaJWangLMaZ, et al
Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant
2017; 32: 475–487.28339863,
XiaJWangLMaZ, et al
Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant
2017; 32: 475–487.28339863
-
A.
Sabatino,
G.
Regolisti,
T.
Karupaiah,
Sharmela
Sahathevan,
B.
Singh,
B.
Khor,
N.
Salhab,
M.
Karavetian,
A.
Cupisti,
E.
Fiaccadori
(2017)
Protein-energy wasting and nutritional supplementation in patients with end-stage renal disease on hemodialysis.
Clinical nutrition, 36 3
-
Yu-Feng
Wei,
Jung-Yueh
Chen,
Ho-Shen
Lee,
Jiun-Ting
Wu,
Chi-Kuei
Hsu,
Yao-Chun
Hsu
(2018)
Association of chronic kidney disease with mortality risk in patients with lung cancer: a nationwide Taiwan population-based cohort study
BMJ Open, 8
-
M.
Tamiya,
A.
Tamiya,
Takako
Inoue,
M.
Kimura,
K.
Kunimasa,
K.
Nakahama,
Y.
Taniguchi,
T.
Shiroyama,
S.
Isa,
K.
Nishino,
T.
Kumagai,
Hidekazu
Suzuki,
T.
Hirashima,
S.
Atagi,
F.
Imamura
(2018)
Metastatic site as a predictor of nivolumab efficacy in patients with advanced non-small cell lung cancer: A retrospective multicenter trial
PLoS ONE, 13
-
(
FelipEArdizzoniACiuleanuT, et al
CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer
2020; 127: 160–172.32028209)
FelipEArdizzoniACiuleanuT, et al
CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer
2020; 127: 160–172.32028209
FelipEArdizzoniACiuleanuT, et al
CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer
2020; 127: 160–172.32028209,
FelipEArdizzoniACiuleanuT, et al
CheckMate 171: a phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations. Eur J Cancer
2020; 127: 160–172.32028209
-
Gisquet,
Rey,
Jougla,
Aubry
(2012)
Où meurt-on en France ? Analyse des certificats de décès (1993-2008).
-
(
PawelecG
Hallmarks of human “immunosenescence”: adaptation or dysregulation?
Immun Ageing
2012; 9: 15.22830639)
PawelecG
Hallmarks of human “immunosenescence”: adaptation or dysregulation?
Immun Ageing
2012; 9: 15.22830639
PawelecG
Hallmarks of human “immunosenescence”: adaptation or dysregulation?
Immun Ageing
2012; 9: 15.22830639,
PawelecG
Hallmarks of human “immunosenescence”: adaptation or dysregulation?
Immun Ageing
2012; 9: 15.22830639
-
(
WangSHuCXieF, et al
Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer. Onco Targets Ther
2020; 13: 667–683.32158220)
WangSHuCXieF, et al
Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer. Onco Targets Ther
2020; 13: 667–683.32158220
WangSHuCXieF, et al
Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer. Onco Targets Ther
2020; 13: 667–683.32158220,
WangSHuCXieF, et al
Use of programmed death receptor-1 and/or programmed death ligand 1 inhibitors for the treatment of brain metastasis of lung cancer. Onco Targets Ther
2020; 13: 667–683.32158220
-
(
GandhiLGarassinoMC
Pembrolizumab plus chemotherapy in lung cancer. N Engl J Med
2018; 379: e18.)
GandhiLGarassinoMC
Pembrolizumab plus chemotherapy in lung cancer. N Engl J Med
2018; 379: e18.
GandhiLGarassinoMC
Pembrolizumab plus chemotherapy in lung cancer. N Engl J Med
2018; 379: e18.,
GandhiLGarassinoMC
Pembrolizumab plus chemotherapy in lung cancer. N Engl J Med
2018; 379: e18.
-
Visit SAGE journals online journals.sagepub.com/ home/tam
-
C.
Locher,
D.
Debieuvre,
D.
Coëtmeur,
F.
Goupil,
O.
Molinier,
T.
Collon,
C.
Dayen,
J.
Treut,
B.
Asselain,
F.
Martin,
F.
Blanchon,
M.
Grivaux
(2013)
Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies.
Lung cancer, 81 1
-
M.
Postow,
M.
Callahan,
J.
Wolchok
(2015)
Immune Checkpoint Blockade in Cancer Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
-
A.
Shirali,
M.
Perazella,
S.
Gettinger
(2016)
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 68 2
-
H.
Tawbi,
P.
Forsyth,
A.
Algazi,
O.
Hamid,
S.
Hodi,
S.
Moschos,
N.
Khushalani,
K.
Lewis,
C.
Lao,
M.
Postow,
M.
Atkins,
M.
Ernstoff,
D.
Reardon,
I.
Puzanov,
R.
Kudchadkar,
R.
Thomas,
A.
Tarhini,
A.
Pavlick,
Joel
Jiang,
A.
Avila,
Sheena
Demelo,
K.
Margolin
(2018)
Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
The New England Journal of Medicine, 379
-
(
BarlesiFDixmierADebieuvreD, et al
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. OncoImmunology
2020; 9: 1744898.)
BarlesiFDixmierADebieuvreD, et al
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. OncoImmunology
2020; 9: 1744898.
BarlesiFDixmierADebieuvreD, et al
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. OncoImmunology
2020; 9: 1744898.,
BarlesiFDixmierADebieuvreD, et al
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study. OncoImmunology
2020; 9: 1744898.
-
(
ChouaidCDebieuvreDDurand-ZaleskiI, et al
Survival inequalities in patients with lung cancer in France: a nationwide cohort study (the TERRITOIRE study). PLoS One
2017; 12: e0182798.28841679)
ChouaidCDebieuvreDDurand-ZaleskiI, et al
Survival inequalities in patients with lung cancer in France: a nationwide cohort study (the TERRITOIRE study). PLoS One
2017; 12: e0182798.28841679
ChouaidCDebieuvreDDurand-ZaleskiI, et al
Survival inequalities in patients with lung cancer in France: a nationwide cohort study (the TERRITOIRE study). PLoS One
2017; 12: e0182798.28841679,
ChouaidCDebieuvreDDurand-ZaleskiI, et al
Survival inequalities in patients with lung cancer in France: a nationwide cohort study (the TERRITOIRE study). PLoS One
2017; 12: e0182798.28841679
-
I.
Gioulbasanis,
Vickie
Baracos,
Z.
Giannousi,
A.
Xyrafas,
Lisa
Martin,
V.
Georgoulias,
D.
Mavroudis
(2011)
Baseline nutritional evaluation in metastatic lung cancer patients: Mini Nutritional Assessment versus weight loss history.
Annals of oncology : official journal of the European Society for Medical Oncology, 22 4